公开(公告)号：US20160289297A1

公开(公告)日：2016-10-06

申请号：US14444431

申请日：2014-07-28

Applicant: DUKE UNIVERSITY

Inventor： Bruce A. Sullenger ,  Shahid Nimjee ,  Sabah Oney ,  Nanette Que-Gewirth

IPC: C07K14/705

CPC classification number: C07K14/70557 ,  A61K31/7088 ,  A61K31/711 ,  C07H21/00 ,  C07H21/04 ,  C12N15/113 ,  C12N15/115 ,  C12N2310/113 ,  C12N2310/16 ,  C12N2310/322 ,  C12N2310/3533

Abstract: The present invention relates, in general, to receptors and to platelet aggregation and, in particular, to a method of inhibiting platelet aggregation using an aptamer that binds to and inhibits the activity of a receptor, such as glycoprotein IIb/IIIa (gpIIb/IIIa), and to aptamers suitable for use in such a method. The invention also relates to antidotes to antiplatelet agents and to methods of using such antidotes to reverse aptamer-induced platelet inhibition. The invention further relates to von Willebrand Factor (VWF) inhibitors, and antidotes therefore, and to methods of using same.

Abstract translation: 本发明一般涉及受体和血小板聚集，特别涉及使用结合并抑制受体（例如糖蛋白IIb / IIIa（gpIIb / IIIa））的活性的适体抑制血小板聚集的方法 ）以及适用于这种方法的适体。 本发明还涉及抗血小板剂的解毒剂以及使用这种解毒剂来逆转适体诱导的血小板抑制的方法。 本发明还涉及血管性血友病因子（VWF）抑制剂和解毒剂，以及其使用方法。

公开(公告)号：US20160250165A1

公开(公告)日：2016-09-01

申请号：US15154539

申请日：2016-05-13

Applicant: DUKE UNIVERSITY

Inventor： Bruce A. Sullenger ,  Sabah Oney ,  Tung Suet Ruby Lam ,  Kam Leong

IPC: A61K31/164 ,  C12N15/115 ,  G01N33/53 ,  A61K31/14 ,  A61K31/132

CPC classification number: A61K31/164 ,  A61K31/00 ,  A61K31/132 ,  A61K31/14 ,  A61K38/00 ,  C07K14/46 ,  C12N15/111 ,  C12N15/115 ,  C12N2310/16 ,  C12N2320/50 ,  G01N33/5308 ,  G01N33/94 ,  G01N2500/00 ,  G01N2500/20

Abstract: The present invention relates, in general, to agents that modulate the pharmacological activity of nucleic acid molecules and, in particular, to agents that bind therapeutic or diagnostic nucleic acid molecules in a sequence independent manner and modulate (e.g., inhibit or reverse) their activity. The invention also relates to compositions comprising such agents and to methods of using same.

Abstract translation: 本发明一般涉及调节核酸分子的药理学活性的试剂，特别是涉及以不依赖序列的方式结合治疗或诊断核酸分子并调节（例如抑制或逆转）其活性的试剂 。 本发明还涉及包含这些试剂的组合物及其使用方法。

公开(公告)号：US09901553B2

公开(公告)日：2018-02-27

申请号：US15154539

申请日：2016-05-13

Applicant: DUKE UNIVERSITY

Inventor： Bruce A. Sullenger ,  Sabah Oney ,  Tung Suet Ruby Lam ,  Kam Leong

IPC: C12N15/11 ,  A61K31/164 ,  A61K31/00 ,  C07K14/46 ,  G01N33/53 ,  G01N33/94 ,  A61K31/132 ,  A61K31/14 ,  C12N15/115 ,  A61K38/00

CPC classification number: A61K31/164 ,  A61K31/00 ,  A61K31/132 ,  A61K31/14 ,  A61K38/00 ,  C07K14/46 ,  C12N15/111 ,  C12N15/115 ,  C12N2310/16 ,  C12N2320/50 ,  G01N33/5308 ,  G01N33/94 ,  G01N2500/00 ,  G01N2500/20

Abstract: The present invention relates, in general, to agents that modulate the pharmacological activity of nucleic acid molecules and, in particular, to agents that bind therapeutic or diagnostic nucleic acid molecules in a sequence independent manner and modulate (e.g., inhibit or reverse) their activity. The invention also relates to compositions comprising such agents and to methods of using same.

公开(公告)号：US09873727B2

公开(公告)日：2018-01-23

申请号：US14444431

申请日：2014-07-28

Applicant: DUKE UNIVERSITY

Inventor： Bruce A. Sullenger ,  Shahid Nimjee ,  Sabah Oney ,  Nanette Que-Gewirth

IPC: C12N15/115 ,  C07K14/705 ,  C07H21/00 ,  C07H21/04 ,  A61K31/7088 ,  A61K31/711 ,  C12N15/113

CPC classification number: C07K14/70557 ,  A61K31/7088 ,  A61K31/711 ,  C07H21/00 ,  C07H21/04 ,  C12N15/113 ,  C12N15/115 ,  C12N2310/113 ,  C12N2310/16 ,  C12N2310/322 ,  C12N2310/3533

Abstract: The present invention relates, in general, to receptors and to platelet aggregation and, in particular, to a method of inhibiting platelet aggregation using an aptamer that binds to and inhibits the activity of a receptor, such as glycoprotein IIb/IIIa (gpIIb/IIIa), and to aptamers suitable for use in such a method. The invention also relates to antidotes to antiplatelet agents and to methods of using such antidotes to reverse aptamer-induced platelet inhibition. The invention further relates to von Willebrand Factor (VWF) inhibitors, and antidotes therefore, and to methods of using same.